Skip to main content

Advertisement

Log in

Rituximab therapy for IgA-vasculitis with nephritis: a case series and review of the literature

  • Therapeutic Aspects in Autoimmunity
  • Published:
Immunologic Research Aims and scope Submit manuscript

Abstract

Henoch–Schonlein purpura, also called IgA-vasculitis, is a systemic small vessels vasculitis with immunoglobulin A1-dominant immune deposits. The optimal treatment remains controversial. Because IgA-vasculitis is characterized by leukocyte infiltration of the blood vessel walls along with immunoglobulin A deposition, and because glucocorticosteroids inhibit inflammatory processes, early administration of glucocorticosteroids has been postulated to be effective, but this indication remains controversial. Immunosuppressive agents (azathioprine, cyclophosphamide, cyclosporine, mycophenolate) have been used in combination with glucocorticosteroids without definitive evidence of effectiveness. The efficacy of rituximab in adult IgA-vasculitis has been reported in few cases. We described a monocentric experience on the use of rituximab in adult IgA-vasculitis with biopsy-proven nephritis. The patients achieved a complete remission of nephritis and syndromic manifestations, and no patients experienced adverse reactions. These data have been compared with the limited literature nowadays available.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, Hagen EC, Hoffman GS, Hunder GG, Kallenberg CG, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37(2):187–92.

    Article  CAS  PubMed  Google Scholar 

  2. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 Revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1–11.

    Article  CAS  PubMed  Google Scholar 

  3. Pillebout E, Nochy D, Thervet E. Henoch–Shönlein purpura. Nephrol Ther. 2009;5(7):663–75.

    Article  PubMed  Google Scholar 

  4. Yang YH, Yu HH, Chiang BL. The diagnosis and classification of Henoch–Schönlein purpura: an updated review. Autoimmun Rev. 2014;13(4–5):355–8.

    Article  PubMed  Google Scholar 

  5. Saulsbury FT. Henoch–Schönlein purpura. Curr Opin Rheumatol. 2010;22(5):598–602.

    Article  PubMed  Google Scholar 

  6. Pillebout E, Verine J. Henoch–Schönlein purpura in the adult. Rev Med Interne. 2014;35(6):372–81.

    Article  CAS  PubMed  Google Scholar 

  7. Calvo-Río V, Loricera J, Mata C, Martín L, Ortiz-Sanjuán F, Alvarez L, et al. Henoch–Schönlein purpura in northern Spain: clinical spectrum of the disease in 417 patients from a single center. Medicine (Baltimore). 2014;93(2):106–13.

    Article  Google Scholar 

  8. Michel BA, Hunder GG, Bloch DA, Calabrese LH. Hypersensitivity vasculitis and Henoch–Schönlein purpura: a comparison between the 2 disorders. J Rheumatol. 1992;19(5):721–8.

    CAS  PubMed  Google Scholar 

  9. Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, Hölttä T, et al. Outcome of Henoch–Schönlein purpura 8 years after treatment with a placebo or prednisone at disease onset. Pediatr Nephrol. 2012;27(6):933–9.

    Article  PubMed  Google Scholar 

  10. Audemard-Verger A, Pillebout E, Guillevin L, Thervet E, Terrier B. IgA vasculitis (Henoch–Shönlein purpura) in adults: diagnostic and therapeutic aspects. Autoimmun Rev. 2015;14(7):579–85.

    Article  CAS  PubMed  Google Scholar 

  11. KDIGO clinical practice guideline for glomerulonephritis. Chapter 11: Henoch–Schönlein purpura nephritis. Kidney Int Suppl 2012;2:218–20.

  12. Ronkainen J, Koskimies O, Ala-Houhala M, Antikainen M, Merenmies J, Rajantie J, Ormälä T, Turtinen J, Nuutinen M. Early prednisone therapy in Henoch–Schönlein purpura: a randomized, double-blind, placebo-controlled trial. J Pediatr. 2006;149(2):241–7.

    Article  CAS  PubMed  Google Scholar 

  13. Dudley J, Smith G, Llewellyn-Edwards A, Tizard E. Randomized placebo controlled trial to assess the role of early prednisone on the development and progression of Henoch–Schonlein purpura nephritis. Pediatr Nephrol. 2007;22:1457.

    Google Scholar 

  14. Huber AM, King J, McLaine P, Klassen T, Pothos M. A randomized, placebo-controlled trial of prednisone in early Henoch Schönlein Purpura [ISRCTN85109383]. BMC Med. 2004;2:7.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Nikibakhsh AA, Mahmoodzadeh H, Karamyyar M, Hejazi S, Noroozi M, Macooie AA. Treatment of severe Henoch–Schonlein purpura nephritis with mycophenolate mofetil. Saudi J Kidney Dis Transplant. 2014;25(4):858–63.

    Article  Google Scholar 

  16. Ohara S, Kawasaki Y, Miyazaki K, Ono A, Suzuki Y, Suyama K, et al. Efficacy of cyclosporine A for steroid-resistant severe Henoch–Schönlein purpura nephritis. Fukushima J Med Sci. 2013;59(2):102–7.

    Article  PubMed  Google Scholar 

  17. Floege J, Feehally J. Treatment of IgA nephropathy and Henoch–Schönlein nephritis. Nat Rev Nephrol. 2013;9(6):320–7.

    Article  CAS  PubMed  Google Scholar 

  18. Iaccarino L, Rampudda M, Canova M, Della Libera S, Sarzi-Puttinic P, Doria A. Mycophenolate mofetil: What is its place in the treatment of autoimmune rheumatic diseases? Autoimmun Rev. 2007;6(3):190–5.

    Article  CAS  PubMed  Google Scholar 

  19. Halling SE, Söderberg MP, Berg UB. Treatment of severe Henoch-Schönlein and immunoglobulin A nephritis. A single center experience. Pediatr Nephrol. 2009;24(1):91–7.

    Article  Google Scholar 

  20. Modena V, Bianchi G, Roccatello D. Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target? Autoimmun Rev. 2013;12(8):793–5.

    Article  Google Scholar 

  21. Kattah AG, Fervenza FC, Roccatello D. Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases. Autoimmun Rev. 2013;12(8):854–9.

    Article  CAS  PubMed  Google Scholar 

  22. Isenberg DA. Rituximab—it was the best of times, it was the worst of times. Autoimmun Rev. 2012;11(11):790–1.

    Article  CAS  PubMed  Google Scholar 

  23. Kamal A, Khamashta M. The efficacy of novel B cell biologics as the future of SLE treatment: a review. Autoimmun Rev. 2014;13(11):1094–101.

    Article  CAS  PubMed  Google Scholar 

  24. Roccatello D, Sciascia S, Baldovino S, Rossi D, Alpa M, Naretto C, Di Simone D, Simoncini M, Menegatti E. A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment—clinical response compared to literature and immunological re-assessment. Autoimmun Rev. 2015;14(12):1123–30.

    Article  CAS  PubMed  Google Scholar 

  25. Niaudet P, Habib R. Methylprednisolone pulse therapy in the treatment of severe forms of Schönlein–Henoch purpura nephritis. Pediatr Nephrol. 1998;12(3):238–43.

    Article  CAS  PubMed  Google Scholar 

  26. Geetha D, Specks U, Stone JH, Merkel PA, Seo P, Spiera R, et al. Rituximab for ANCA-Associated Vasculitis Immune Tolerance Network Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. J Am Soc Nephrol. 2015;26(4):976–85.

    Article  CAS  PubMed  Google Scholar 

  27. Sinico RA, Di Toma L, Radice A. Renal involvement in anti-neutrophil cytoplasmic autoantibody associated vasculitis. Autoimmun Rev. 2013;12(4):477–82.

    Article  CAS  PubMed  Google Scholar 

  28. Gómez-Puerta JA, Quintana LF, Stone JH, Ramos-Casals M, Bosch X. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach. Autoimmun Rev. 2012;11(9):646–52.

    Article  PubMed  Google Scholar 

  29. Rutgers A, Kallenberg CG. Refractory vasculitis. Autoimmun Rev. 2011;10(11):702–6.

    Article  PubMed  Google Scholar 

  30. Dumoitier N, Terrier B, London J, Lofek S, Mouthon L. Implication of B lymphocytes in the pathogenesis of ANCA-associated vasculitides. Autoimmun Rev. 2015;14(11):996–1004.

    Article  CAS  PubMed  Google Scholar 

  31. Pietrogrande M, De Vita S, Zignego AL, Pioltelli P, Sansonno D, Roccatello D, et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev. 2011;10(8):444–54.

    Article  PubMed  Google Scholar 

  32. Pani A, Roccatello D, Fervenza F, Lin J, Sethi S. IgA nephropathy and Schonlein–Henoch purpura nephritis. In: Singh A, editor. Core concepts in parenchymal kidney disease. New York: Springer; 2014.

    Google Scholar 

  33. Eisenberg R, Looney RJ. The therapeutic potential of anti-CD20 “what do B-cells do?”. Clin Immunol (Orlando, FL). 2005;117(3):207–13.

    Article  CAS  Google Scholar 

  34. Di Gaetano N, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol (Baltimore, MD: 1950). 2003;171(3):1581–7.

    Article  Google Scholar 

  35. Ozen S, Pistorio A, Lusan SM, Bakkaloglu A, Herlin T, Brik R, et al. EULAR/PRINTO/PRES criteria for Henoch–Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Paediatric Rheumatology International Trials Organisation (PRINTO). Ann Rheum Dis. 2010;69(5):798–806.

    Article  PubMed  Google Scholar 

  36. Bluman J, Goldman RD. Henoch–Schönlein purpura in children: limited benefit of corticosteroids. Can Fam Physician. 2014;60(11):1007–10.

    PubMed  PubMed Central  Google Scholar 

  37. Kato-Okada S, Suzuki H, Inoue T, Kikuta T, Okada H. Successful prednisolone therapy in elderly patients with severe forms of Henoch–Schönlein purpura nephritis. Jpn Clin Med. 2015;6(6):5–7.

    PubMed  PubMed Central  Google Scholar 

  38. Chartapisak W, Opastiraku S, Willis NS, Craig JC, Hodson EM. Prevention and treatment of renal disease in Henoch–Schönlein purpura: a systematic review. Arch Dis Child. 2009;94(2):132–7.

    Article  CAS  PubMed  Google Scholar 

  39. Zaffanello M, Fanos V. Treatment-based literature of Henoch–Schönlein purpura nephritis in childhood. Pediatr Nephrol. 2009;24(10):1901–11.

    Article  PubMed  Google Scholar 

  40. Bogdanović R. Henoch-Schönlein purpura nephritis in children: risk factors, prevention and treatment. Acta Paediatr. 2009;98(12):1882–9.

    Article  PubMed  Google Scholar 

  41. Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, Hölttä T, Jahnukainen T, Rajantie J, Ormälä T, Nuutinen M. Clinical course of extrarenal symptoms in Henoch–Schonlein purpura: a 6-month prospective study. Arch Dis Child. 2010;95(11):871–6.

    Article  PubMed  Google Scholar 

  42. Jauhola O, Ronkainen J, Autio-Harmainen H, Koskimies O, Ala-Houhala M, Arikoski P, et al. Cyclosporine A vs. methylprednisolone for Henoch–Schönlein nephritis: a randomized trial. Pediatr Nephrol. 2011;26(12):2159–66.

    Article  PubMed  Google Scholar 

  43. Roccatello D, Ferro M, Coppo R, Giraudo G, Quattrocchio G, Piccoli G. Report on intensive treatment of extracapillary glomerulonephritis with focus on crescentic IgA nephropathy. Nephrol Dial Transplant. 1995;10(11):2054–9.

    CAS  PubMed  Google Scholar 

  44. Shenoy M, Ognjanovic MV, Coulthard MG. Treating severe Henoch–Schönlein and IgA nephritis with plasmapheresis alone. Pediatr Nephrol. 2007;22(8):1167–71.

    Article  PubMed  Google Scholar 

  45. Gianviti A, Trompeter RS, Barratt TM, Lythgoe MF, Dillon MJ. Retrospective study of plasma exchange in patients with idiopathic rapidly progressive glomerulonephritis and vasculitis. Arch Dis Child. 1996;75(3):186–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Han F, Chen LL, Ren PP, Le JY, Choong PJ, Wang HJ, et al. Mycophenolate mofetil plus prednisone for inducing remission of Henoch–Schönlein purpura nephritis: a retrospective study. J Zhejiang Univ Sci B. 2015;16(9):772–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Quartuccio L, Zuliani F, Corazza L, Scaini P, Zani R, Lenzi M, et al. Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: long-term follow up data of a randomized controlled multicentre study. J Autoimmun. 2015;63:88–93.

    Article  CAS  PubMed  Google Scholar 

  48. Ferri C, Cacoub P, Mazzaro C, Roccatello D, Scaini P, Sebastiani M, et al. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun Rev. 2011;11(1):48–55.

    Article  CAS  PubMed  Google Scholar 

  49. Yang YH, Chuang YH, Wang LC, Huang HY, Gershwin ME, Chiang BL. The immunobiology of Henoch–Schönlein purpura. Autoimmun Rev. 2008;7(3):179–84.

    Article  CAS  PubMed  Google Scholar 

  50. Wierciński R, Zoch-Zwierz W, Wasilewska A, Tomaszewska B, Winiecka W, Stasiak-Barmuta A, et al. Lymphocyte subpopulations of peripheral blood in children with Schönlein–Henoch purpura and IgA nephropathy. Pol Merkur Lekarski. 2001;10(58):244–6.

    PubMed  Google Scholar 

  51. Sun XC, Chen MY, Cheng AS, Xu DL. Immunologic changes in children with Henoch–Schonlein purpura in the acute stage. Chin Med J (Engl). 1989;102(7):533–6.

    CAS  Google Scholar 

  52. Bellan M, Pirisi M, Sainaghi PP. Long-term remission of corticosteroid- and cyclophosphamide-resistant Henoch-Schönlein purpura with rituximab. Scand J Rheumatol. 2015;27:1–2.

    Google Scholar 

  53. Ishiguro H, Hashimoto T, Akata M, Suzuki S, Azushima K, Kobayashi Y, et al. Rituximab treatment for adult purpura nephritis with nephrotic syndrome. Intern Med. 2013;52(10):1079–83.

    Article  PubMed  Google Scholar 

  54. Pindi Sala T, Michot JM, Snanoudj R, Dollat M, Estève E, Marie B, et al. Successful outcome of a corticodependent Henoch–Schönlein purpura adult with rituximab. Case Rep Med. 2014;2014:619218.

    PubMed  PubMed Central  Google Scholar 

  55. Pillebout E, Rocha F, Fardet L, Rybojad M, Verine J, Glotz D. Successful outcome using rituximab as the only immunomodulation in Henoch–Schonlein purpura: case report. Nephrol Dial Transplant. 2011;26(6):2044–6.

    Article  CAS  PubMed  Google Scholar 

  56. Donnithorne KJ, Atkinson TP, Hinze CH, Nogueira JB, Saeed SA, Askenazi DJ, et al. Rituximab therapy for severe refractory chronic Henoch–Schönlein purpura. J Pediatr. 2009;155(1):136–9.

    Article  CAS  PubMed  Google Scholar 

  57. Hinze CH, Colbert RA. B-cell depletion in Wegener’s granulomatosis. Clin Rev Allergy Immunol. 2008;34(3):372–9.

    Article  PubMed  Google Scholar 

  58. Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211–20.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Dario Roccatello.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest, nor any financial interest with regard to the present paper.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fenoglio, R., Naretto, C., Basolo, B. et al. Rituximab therapy for IgA-vasculitis with nephritis: a case series and review of the literature. Immunol Res 65, 186–192 (2017). https://doi.org/10.1007/s12026-016-8827-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12026-016-8827-5

Keywords

Navigation